19:52 , Jan 17, 2019 |  BioCentury  |  Regulation

Products on shutdown standby

Products on shutdown standby On Jan. 14, FDA said it has reserves to continue drug reviews for five more weeks if the government shutdown continues. There are at least six PDUFA dates for new products...
00:33 , Sep 28, 2018 |  BC Innovations  |  Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
18:30 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Sanofi's Cablivi gains EU approval, Priority Review in U.S.

Sanofi (Euronext:SAN; NYSE:SNY) said the European Commission approved Cablivi caplacizumab to treat rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP). The company also revealed Sept. 3 that FDA accepted and granted Priority Review to...
18:18 , Sep 3, 2018 |  BC Extra  |  Company News

Sanofi's Cablivi gains EU approval, Priority Review in U.S.

Sanofi (Euronext:SAN; NYSE:SNY) said the European Commission approved Cablivi caplacizumab to treat rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP). The company also revealed Monday that FDA accepted and granted Priority Review to its...
18:19 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Mouse studies suggest ZFP36 inhibitors could help treat acute lymphocytic choriomeningitis virus (LCMV) infection. In a mouse model of acute LCMV infection, systemic ZFP36 knockout increased the number of LCMV-specific CD4 +...
01:06 , Feb 8, 2018 |  BC Extra  |  Company News

Cardio/diabetes sales drag down Sanofi earnings

On the heels of a pair of proposed multibillion dollar acquisitions, Sanofi (Euronext:SAN; NYSE:SNY) reported earnings that missed analyst forecasts as the company grapples with a decline in sales for its diabetes and cardiovascular business...
20:31 , Feb 2, 2018 |  BC Week In Review  |  Company News

Sanofi to acquire Ablynx in €3.9B deal

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire Nanobodies company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) for €45 per share in cash, or about €3.9 billion ($4.8 billion). The price is a 21% premium to Ablynx's close of...
23:11 , Jan 29, 2018 |  BC Extra  |  Company News

Sanofi to acquire Ablynx in €3.9B deal

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire Nanobodies company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) for €45 per share in cash, or about €3.9 billion ($4.84 billion). The price is a 21% premium to Ablynx's close of...
18:24 , Jan 12, 2018 |  BC Week In Review  |  Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) made public news that its board rejected two unsolicited acquisition proposals from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Ablynx said in a statement the latest proposal "fundamentally undervalues" the company. On Dec....
22:53 , Jan 8, 2018 |  BC Extra  |  Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) gained €9.60 (45%) to €30.80 in Brussels and $12.71 (49%) to $38.62 in New York on Monday after making public news that its board rejected two unsolicited acquisition proposals from Novo...